NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free ANIP Stock Alerts $67.34 -0.71 (-1.04%) (As of 05:17 PM ET) Add Compare Share Share Today's Range$67.24▼$69.6050-Day Range$64.58▼$69.6952-Week Range$40.00▼$70.81Volume140,127 shsAverage Volume137,380 shsMarket Capitalization$1.42 billionP/E Ratio42.09Dividend YieldN/APrice Target$80.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get ANI Pharmaceuticals alerts: Email Address ANI Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside20.2% Upside$81.00 Price TargetShort InterestHealthy1.09% of Shares Sold ShortDividend StrengthN/ASustainability-2.48Upright™ Environmental ScoreNews Sentiment0.89Based on 21 Articles This WeekInsider TradingSelling Shares$11.70 M Sold Last QuarterProj. Earnings Growth16.62%From $3.55 to $4.14 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.62 out of 5 starsMedical Sector83rd out of 925 stocksPharmaceutical Preparations Industry26th out of 430 stocks 2.5 Analyst's Opinion Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about ANI Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.09% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 7.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreANI Pharmaceuticals has received a 36.91% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Beta blockers (C07)", "Macrolides", "Antifungal medication (D01) ", "Cyclophosphamide", and "Calcium channel blockers (C08)" products. See details.Environmental SustainabilityThe Environmental Impact score for ANI Pharmaceuticals is -2.48. Previous Next 2.7 News and Social Media Coverage News SentimentANI Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for ANI Pharmaceuticals this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 3 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,695,866.00 in company stock.Percentage Held by Insiders12.70% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 16.62% in the coming year, from $3.55 to $4.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is 42.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.87.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is 42.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 140.28.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ANI Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About ANI Pharmaceuticals Stock (NASDAQ:ANIP)ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Read More ANIP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIP Stock News HeadlinesMay 5, 2024 | insidertrades.comChad Gassert Sells 20,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockMay 4, 2024 | insidertrades.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells 20,000 Shares of StockApril 23, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Sells $1,095,442.53 in StockApril 18, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 7,414 SharesApril 16, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $16,947.50 in StockMay 13 at 8:06 AM | finance.yahoo.comANI Pharmaceuticals Inc (ANIP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...May 13 at 8:06 AM | finance.yahoo.comANI Pharmaceuticals, Inc. Just Beat EPS By 459%: Here's What Analysts Think Will Happen NextMay 13 at 7:13 AM | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Releases FY24 Earnings GuidanceMay 12 at 3:30 AM | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap Up to $65.88May 11 at 12:17 PM | finance.yahoo.comANI Pharmaceuticals First Quarter 2024 Earnings: Beats ExpectationsMay 11 at 12:17 PM | finance.yahoo.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call TranscriptMay 10 at 4:15 PM | finance.yahoo.comANI Pharmaceuticals Reports Strong Q1 2024 Results, Surpassing Revenue ExpectationsMay 10 at 11:12 AM | finanznachrichten.deANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 GuidanceMay 10 at 11:12 AM | sfgate.comANI: Q1 Earnings SnapshotMay 10 at 11:12 AM | markets.businessinsider.comANI Pharmaceuticals, Inc. Q1 Profit Increases, Beats EstimatesMay 10 at 6:50 AM | globenewswire.comANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 GuidanceMay 9, 2024 | finance.yahoo.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies AheadMay 9, 2024 | finance.yahoo.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?May 4, 2024 | americanbankingnews.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Buy" from BrokeragesMay 3, 2024 | americanbankingnews.comANI Pharmaceuticals (ANIP) Set to Announce Earnings on FridayMay 1, 2024 | globenewswire.comANI Pharmaceuticals to Participate at Two Upcoming Healthcare ConferencesApril 27, 2024 | seekingalpha.comANIP ANI Pharmaceuticals, Inc.April 23, 2024 | markets.businessinsider.comEvaluating ANI Pharmaceuticals: Insights From 5 Financial AnalystsApril 19, 2024 | investing.comAni Pharmaceuticals executive sells over $1.5 million in company stockApril 18, 2024 | globenewswire.comANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ETSee More Headlines Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/13/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees642Year FoundedN/APrice Target and Rating Average Stock Price Target$80.00 High Stock Price Target$83.00 Low Stock Price Target$77.00 Potential Upside/Downside+17.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.60 Trailing P/E Ratio42.53 Forward P/E Ratio19.17 P/E GrowthN/ANet Income$18.78 million Net Margins6.87% Pretax Margin8.32% Return on Equity17.15% Return on Assets8.29% Debt Debt-to-Equity Ratio0.63 Current Ratio3.95 Quick Ratio3.12 Sales & Book Value Annual Sales$486.82 million Price / Sales2.95 Cash Flow$6.42 per share Price / Cash Flow10.60 Book Value$21.13 per share Price / Book3.22Miscellaneous Outstanding Shares21,080,000Free Float18,402,000Market Cap$1.43 billion OptionableOptionable Beta0.80 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Nikhil Lalwani (Age 46)President, CEO & Director Comp: $2.32MMr. Stephen P. Carey (Age 53)Senior VP of Finance & CFO Comp: $1.11MMr. Chad Gassert (Age 48)Senior Vice President of Corporate Development & Strategy Comp: $849.71kMr. Christopher K. Mutz (Age 52)Senior Vp & Head of Rare Disease Comp: $867.92kMr. Ori Gutwerg (Age 49)Senior Vice President of Generics Comp: $895.16kMr. Muthusamy Shanmugam MS R.Ph. (Age 56)Head of R&D, COO of Novitium Operations & Director Mr. James G. Marken (Age 61)Senior Vice President of Operations & Product Development Comp: $673.23kMs. Meredith W. Cook (Age 49)Senior VP, General Counsel & Corporate Secretary Ms. Krista L. Davis (Age 50)Senior VP & Chief Human Resources Officer Ms. Elizabeth Powell J.D.Chief Compliance Officer & Head of Legal of Rare DiseaseMore ExecutivesKey CompetitorsArcus BiosciencesNYSE:RCUSKiniksa PharmaceuticalsNASDAQ:KNSADay One BiopharmaceuticalsNASDAQ:DAWNXencorNASDAQ:XNCRMorphicNASDAQ:MORFView All CompetitorsInsiders & InstitutionsHillsdale Investment Management Inc.Sold 1,900 shares on 5/11/2024Ownership: 0.320%Vanguard Group Inc.Bought 17,460 shares on 5/10/2024Ownership: 6.198%William Blair Investment Management LLCSold 292 shares on 5/8/2024Ownership: 2.326%Entropy Technologies LPSold 2,311 shares on 5/8/2024Ownership: 0.023%ProShare Advisors LLCBought 404 shares on 5/8/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions ANIP Stock Analysis - Frequently Asked Questions Should I buy or sell ANI Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANIP shares. View ANIP analyst ratings or view top-rated stocks. What is ANI Pharmaceuticals' stock price target for 2024? 4 brokers have issued 12-month price objectives for ANI Pharmaceuticals' stock. Their ANIP share price targets range from $77.00 to $87.00. On average, they predict the company's stock price to reach $81.00 in the next twelve months. This suggests a possible upside of 20.2% from the stock's current price. View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts. How have ANIP shares performed in 2024? ANI Pharmaceuticals' stock was trading at $55.14 on January 1st, 2024. Since then, ANIP shares have increased by 22.2% and is now trading at $67.37. View the best growth stocks for 2024 here. When is ANI Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our ANIP earnings forecast. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) posted its quarterly earnings data on Thursday, February, 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The specialty pharmaceutical company had revenue of $131.65 million for the quarter, compared to the consensus estimate of $123.02 million. ANI Pharmaceuticals had a trailing twelve-month return on equity of 17.15% and a net margin of 6.87%. What ETFs hold ANI Pharmaceuticals' stock? ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), SPDR S&P Pharmaceuticals ETF (XPH), First Trust Small Cap Growth AlphaDEX Fund (FYC) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has ANI Pharmaceuticals issued on next quarter's earnings? ANI Pharmaceuticals issued an update on its FY24 earnings guidance on Friday, May, 10th. The company provided earnings per share guidance of $4.26-4.67 for the period, compared to the consensus earnings per share estimate of $4.48. The company issued revenue guidance of $520-542 million, compared to the consensus revenue estimate of $535.14 million. What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO? 5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC). Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.20%), William Blair Investment Management LLC (2.33%), Global Alpha Capital Management Ltd. (1.85%), Russell Investments Group Ltd. (0.51%), Principal Financial Group Inc. (0.42%) and Assenagon Asset Management S.A. (0.40%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Krista Davis, Meredith Cook, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh, Stephen P Carey and Thomas Haughey. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANIP) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersElon to Transform U.S. Economy? Porter & CompanyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
